A visual target evaluation report for SRD5A2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.

Toripalimab is a Monoclonal antibody targeting PD-1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Serplulimab is a Monoclonal antibody targeting PD-1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Binimetinib is a Small molecule drug targeting MEK1 x MEK2, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Encorafenib is a Small molecule drug targeting BRAF V600E, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

A visual target evaluation report for SRD5A1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.

Tivozanib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Regorafenib is a Small molecule drug targeting BRAF V600E x CRAF x CSF-1R x DDR2 x EphA2 x FGFR1 x FRK x MAPK11 x PDGFRα x PDGFRβ x RET x Tie-2 x TrkA x.

Avacopan is a Small molecule drug targeting C5AR1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Pegcetacoplan is a Synthetic peptide, Cyclic Peptide targeting C3, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Inebilizumab-cdon is a Monoclonal antibody targeting CD19, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

A visual target evaluation report for SMYD3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.